Cobas 8000 e802

The mean value of the blood pressure (BP) of participants was measured twice in the right arm in the seated position using an oscillometric device (DINAMAP ProCare 200, GE Medical Systems, Milwaukee, WI, USA). Venous blood samples were obtained after 12 hours of fasting to determine the fasting plasma glucose (FPG), fasting plasma insulin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and high-sensitivity C-reactive protein (CRP). FPG was measured using ultraviolet assay with hexokinase (Cobas 8000 C702, Roche, Mannheim, Germany). Insulin was measured using electrochemiluminescence immunoassay (Cobas 8000 e802, Roche, Mannheim, Germany). HDL-C and LDL-C were measured using a homogeneous enzymatic colorimetric test (Cobas 8000 C702, Roche, Mannheim, Germany). TG, AST, ALT, and GGT were measured using enzymatic assay (Cobas 8000 C702, Roche, Mannheim, Germany). CRP was measured using turbidimetric immunoassay (Cobas 8000 C702, Roche, Mannheim, Germany). The homeostasis model assessment for insulin resistance (HOMA-IR) was used to determine insulin sensitivity, and was calculated using the following formula: (FPG Level (in milligrams per deciliter) × Fasting Plasma Insulin Level (in microunits per milliliter))/405.

After participants fasted for 8 to 12 h, venous blood samples were collected from peripheral blood vessels. Obtained blood samples were transferred to the Seegene Medical Foundation (Seoul, South Korea) for analysis. Triglyceride (TG, mg/dL) level was measured in an enzymatic assay (Cobas 8000 C702, Roche, Mannheim, Germany). Level of high-density lipoprotein cholesterol (HDL-C, mg/dL) and low-density lipoprotein cholesterol (LDL-C, mg/dL) were also measured by homogeneous enzymatic colorimetric tests (Cobas 8000 C702, Roche, Mannheim, Germany). Fasting blood glucose (FBG, mg/dL) was measured using an ultraviolet assay with the hexokinase method (Cobas 8000 C702, Roche, Mannheim, Germany). Fasting serum insulin level (μU/mL) was measured by electrochemiluminescence immunoassay (Cobas 8000 E802, Roche, Mannheim, Germany). Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the following formula: (Fasting serum insulin (μU/mL) × Fasting blood glucose (mg/dL))/405.

Venous blood samples were obtained after 12 hours of fasting to determine the fasting plasma glucose (FPG), fasting plasma insulin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and high-sensitivity C-reactive protein (hsCRP). FPG was measured using ultraviolet assay with hexokinase (Cobas 8000 C702, Roche, Mannheim, Germany). Insulin was measured using electrochemiluminescence immunoassay (Cobas 8000 e802, Roche, Mannheim, Germany). HDL-C and LDL-C were measured using a homogeneous enzymatic colorimetric test (Cobas 8000 C702, Roche, Mannheim, Germany). TG, AST, and ALT were measured using enzymatic assay (Cobas 8000 C702, Roche, Mannheim, Germany). hsCRP was measured using turbidimetric immunoassay (Cobas 8000 C702, Roche, Mannheim, Germany). The homeostasis model assessment for insulin resistance (HOMA-IR) was used to determine insulin sensitivity, and was calculated using the following formula: (FPG Level (mg/dL) × Fasting Plasma Insulin Level (uU/mL))/405. Adiponectin was measured using enzyme-linked immunosorbent assay (VersaMax ELISA Microplate Reader, Molecular Devices, San Jose, CA, USA).